scholarly journals Implications of False Negative and False Positive Diagnosis in Lymph Node Staging of NSCLC by Means of 18F-FDG PET/CT

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e78552 ◽  
Author(s):  
Shaolei Li ◽  
Qingfeng Zheng ◽  
Yuanyuan Ma ◽  
Yuzhao Wang ◽  
Yuan Feng ◽  
...  
2019 ◽  
Vol 29 (8) ◽  
pp. 4286-4293 ◽  
Author(s):  
Antoine Girard ◽  
Mathieu Rouanne ◽  
Sarah Taconet ◽  
Camélia Radulescu ◽  
Yann Neuzillet ◽  
...  

2016 ◽  
Vol 15 (3) ◽  
pp. e398 ◽  
Author(s):  
R. Pichler ◽  
T. De Zordo ◽  
J. Fritz ◽  
A. Kroiss ◽  
I. Heidegger ◽  
...  

Lung ◽  
2008 ◽  
Vol 186 (5) ◽  
pp. 327-336 ◽  
Author(s):  
Young-Sil An ◽  
Joo Sung Sun ◽  
Kyung Joo Park ◽  
Sung Chul Hwang ◽  
Kwang Joo Park ◽  
...  

Author(s):  
Jelena Saponjski ◽  
Djuro Macut ◽  
Nebojša Petrovic ◽  
Sanja Ognjanovic ◽  
Bojana Popovic ◽  
...  

IntroductionThe aim was to assess the diagnostic value of 99mTc-Tektrotyd scintigraphy (TCT) and positron emission tomography/computed tomography using F-18 fluorodeoxyglucose (18F-FDG PET/CT) in the detection and follow-up of neuroendocrine tumors (NETs), and their predictive value for disease progression.Material and methodsIn this retrospective cohort, TCT and 18F-FDG PET/CT were performed in 90 patients (37 men, 53 women, mean age 52.7 ±15.1), with NET. Correlation of Ki67 and tumor grade versus Krenning score and SUVmax was assessed, Kaplan-Meier analysis was used for progression-free survival (PFS), and Cox regression analysis was performed to identify the association between progression-related factors and PFS.ResultsOut of 90, true positive TCT was detected in 56 (62.2%) patients, true negative in 19 (21.1%), false positive in 4 (4.4%), false negative in 11 (12.2%), while 18F-FDG PET/CT was true positive in 69 (76.7%) patients, true negative in 10 (11.1%), false positive in 5 (5.5%), false negative in 6 (6.7%). Mean 18F-FDG PET/CT SUVmax was 6.8 ±6.2. Diagnostic sensitivity of TCT was 83.6%, specificity 82.6%, accuracy 83.3% vs. 18F-FDG PET/CT sensitivity was 92.0%, specificity 66.7%, accuracy 87.8%. A significant correlation between Ki67 and SUVmax was found in positive 18F-FDG PET/CT findings, unlike the correlation between Ki67 and Krenning score. Median PFS was 25 months (95% CI: 18.2–31.8), in 18F-FDG PET/CT positive patients 23 months (95% CI: 16.3–29.7) and 18F-FDG PET/CT negative 26 months (p = 0.279). Progression-free survival predictors were SUVmax and Krenning score.ConclusionsIn our study, TCT and 18F-FDG PET/CT have high diagnostic accuracy in detection of NET. Higher Krenning score on TCT and SUVmax in positive 18F-FDG PET/CT findings are predictors of disease progression. 99mTc-Tektrotyd scintigraphy and 18F-FDG PET/CT can be useful complementary tools in management of patients with NETs and in predicting patients’ outcome.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 1278-1278
Author(s):  
Annalisa Balbo-Musetto ◽  
Riccardo Bruna ◽  
Angela Gueli ◽  
Chiara Saviolo ◽  
Massimo Petracchini ◽  
...  

Abstract Background. The assessment of nodal and extranodal involvement in Hodgkin’s (HL) and non-Hodgkin’s (NHL) lymphoma is mostly performed by Computed Tomography with i.v. iodinated contrast agent (CE-CT) and 18F-FDG Positron Emission Tomography (PET), along with bone marrow (BM) biopsy. Both CE-CT and 18F-FDG-PET require the delivery of considerable dose of ionizing radiation, that may be of concern given the increased risk of secondary malignancies in long surviving patients. Whole body Magnetic Resonance Imaging (Wb-MRI) is a novel and promising radiation-free technique and the development of Diffusion Weighted Imaging (DWI) has enhanced its diagnostic potential. At our Institution, Wb-MRI-DWI has been used as additional diagnostic tool in a series of lymphoma patients at disease onset. The diagnostic accuracy of the procedure is here reported. Patients and Methods. From February 2010 to October 2013, 41 patients underwent the Wb-MRI-DWI procedure, which was added to the standard procedures in order to further investigate possible bone, liver and kidney involvement. Median age of the patients was 49 yrs. (20-76), histological subtypes included 10 Diffuse Large B-Cell (DLB-CL), 13 Follicular (FL), 3 Mantle-cell (MCL), 1 Burkitt’s (BL) Lymphoma and 14 HL. All patients received the diagnostic procedures required for staging definition, including CE-CT, BM biopsy, and 18F-FDG-PET co-registered with low dose unenhanced CT. Nodal and extra-nodal sites were considered pathologic according to standard parameters employed for imaging technique evaluation. For the present analysis, the Gold Standard (GS) assessment was defined based on: i. the information obtained primarily by 18F-FDG PET-CT and secondary by CE-CT findings; ii. the BM histological examination; iii. the modifications before and after therapy for those lesions with discordant definition at diagnosis; iv. for few lesions, with uncertain definition at diagnosis a biopsy procedure was performed and histological data were considered true positive. Results. According to GS, among 1,025 nodal regions analyzed in 41 patients, 217 were judged positive for involvement by lymphoma. CE-CT had 22 false negative and 10 false positive errors, whereas Wb-MRI-DWI erroneously considered involved 6 nodes and failed in recognizing 17 localizations, mostly for misdiagnosed nodes in the mediastinum. There were no errors in nodal assessment by 18F-FDG PET-CT. A total of 458 extranodal sites were evaluated and 37 were considered positive. Compared to GS, 18F-FDG PET-CT had four false negative errors, i.e. no detection of BM (three cases) and spleen (one case) involvement; in addition, 18FDG PET-CT had two false positive results, due to presumed tonsil and BM involvement that were not confirmed on histological examination. CE-CT had 17 false negative errors mainly due to misdiagnosis of BM involvement in 13 out of 14 BM positive cases. Other false negative errors with CE-CT were lack of disease detection in the spleen (1 case), oropharyx (2 cases) and vulva (1 case). Wb-MRI-DWI was unable to detect the gastric involvement in one patient, while no false positive were recorded. The comparative analysis indicates that: i.18F-FDG PET-CT alone overstaged two patients (4.9%) (wrong involvement in BM and tonsil), two patients were understaged due to the failure in recognizing BM involvement; ii. CE-CT alone understaged 12 patients (29%), mainly due to low sensibility in detecting BM involvement; no patient was overstaged by CE-CT; iii. Wb-MRI-DWI alone, in spite of the 24 errors, mainly in nodal misdiagnosis, did not fail the final per-patient staging assessment. Wb-MRI-DWI proved to be the most reliable imaging technique for BM evaluation, with no misjudgment recorded, while 18F-FDG PET-TC was unable to correctly assess BM involvement in four patients and CE-CT in 13. Conclusion. The data indicate that Wb-MRI-DWI is a sensitive and specific imaging technique for malignant lymphoma evaluation. Compared to CE-CT, it detects additional disease that modify clinical stage in a significant percentage of patients, altering their management and outcome. Wb-MRI-DWI is also extremely effective in detecting BM involvement. Thanks to the lack of any radiation exposure and intravenous contrast agent injection, the results here reported further support the use of Wb-MRI-DWI in place of CE-CT for the staging and possibly the follow up monitoring of malignant lymphoma. Disclosures No relevant conflicts of interest to declare.


2014 ◽  
Vol 53 (03) ◽  
pp. 89-94 ◽  
Author(s):  
D. H. Lee ◽  
J.-K Yoon ◽  
S. J. Lee ◽  
T. H. Kim ◽  
D. K. Kang ◽  
...  

SummaryThe aim of this study was to evaluate the diagnostic abilities of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) compared with those of ultrasonography and magnetic resonance imaging (MRI) for axillary lymph node staging in breast cancer patients. Patients, methods: Pre- operative 18F-FDG PET/non-contrast CT, ultrasonography and MRI were performed in 215 women with breast cancer. Axillary lymph node dissection was performed in all patients and the diagnostic performance of each modality was evaluated using histopathologic assessments as the reference standard. ROC curves were compared to evaluate the diagnostic ability of several imaging modalities (i. e., ultrasonography, MRI and 18F-FDG PET/CT). Results: In total, 132 patients (61.4%) had axillary lymph node metastasis. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for the detection of axillary lymph node metastasis were 72.3%, 77.3%, 66.7%, 81.6%, 75.3% for ultrasonography, 67.5%, 78.0%, 65.9%, 79.2%, 74.0% for MRI, and 62.7%, 88.6%, 77.6%, 79.1%, 78.6% for 18F-FDG PET/CT, respectively. There was no significant difference in diagnostic ability among the imaging modalities (i.e., ultrasonography, MRI and 18F-FDG PET/CT). The diagnostic ability of 18F-FDG PET/CT was significantly improved by combination with MRI (p = 0.0002) or ultrasonography (p < 0.0001). The combination of 18F-FDG PET/CT with ultrasonography had a similar diagnostic ability to that of all three modalities combined (18F-FDG PET/CT+ultraso- nography+MRI, p = 0.05). Conclusion: The diagnostic performance of 18F-FDG PET/CT for detection of axillary node metastasis was not significantly different from that of ultrasonography or MRI in breast cancer patients. Combining 18F-FDG PET/CT with ultrasonography or MRI could improve the diagnostic performance compared to 18F-FDG PET/CT alone.


2018 ◽  
Vol 43 (12) ◽  
pp. e482-e483
Author(s):  
Raja Senthil ◽  
H Ramesh ◽  
Arun Visakh R. ◽  
Thara Pratap ◽  
Pushpa Mahadevan

2016 ◽  
Vol 41 (4) ◽  
pp. e181-e186 ◽  
Author(s):  
Suzana Cipriano Teixeira ◽  
Bas B. Koolen ◽  
Wouter V. Vogel ◽  
Jelle Wesseling ◽  
Marcel P. M. Stokkel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document